Arcus Biosciences
RCUS
173 hedge funds and large institutions have $1.33B invested in Arcus Biosciences in 2022 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 64 increasing their positions, 32 reducing their positions, and 35 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 32
51% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 35
10% more funds holding
Funds holding: 157 → 173 (+16)
1.88% more ownership
Funds ownership: 71.25% → 73.13% (+1.9%)
16% less capital invested
Capital invested by funds: $1.59B → $1.33B (-$259M)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
39% less call options, than puts
Call options by funds: $17.6M | Put options by funds: $28.9M
Top Buyers
| 1 |
BlackRock
New York
|
+$97.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$41.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.9M |
| 4 |
Goldman Sachs
New York
|
+$17.8M |
| 5 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$13.1M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$103M |
| 2 |
AI
Alphabet Inc
Mountain View,
California
|
-$80.9M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$28.8M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$25.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$23.9M |
RCUS Hedge Fund Activity: Q2 2022 in Review
173 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2022, worth a combined $1.33B — down 16% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new RCUS positions and 35 closed out — a net gain of 18 holders — while 64 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $97.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $103M sold.
- 173 institutional investors held Arcus Biosciences (RCUS) as of Q2 2022, up from 157 in Q1 2022.
- Funds reported $1.33B of Arcus Biosciences stock for Q2 2022, down 16% quarter-over-quarter.
- 53 funds opened new Arcus Biosciences positions in Q2 2022 and 35 closed out, a net change of +18 holders.
- The largest Arcus Biosciences buyer in Q2 2022 was BlackRock, an estimated $97.5M added.
- The largest Arcus Biosciences seller in Q2 2022 was EcoR1 Capital, an estimated $103M sold.
Based on aggregated 13F filings for Q2 2022.